You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

192 Results
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Feb 2026
Drug
Other Name(s): Opdivo®
Jan 2026
Drug
Other Name(s): Zoladex® , Zoladex® LA
Mar 2026
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    goserelin
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Mar 2026
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    goserelin
Mar 2026

Pages